E-LIB Suche - Ergebnisse für: Shenoy, Chaitra S.

1

Rational design of bimetallic alloys for effective hydrodec..:

Shenoy, Chaitra S. ; Gupta, Shelaka ; Haider, M. Ali.
New Journal of Chemistry. 48 (2024) 17 - p. 7799-7809 , 2024

2

Understanding the origin of structure sensitivity in hydrod..:

Shenoy, Chaitra S. ; Khan, Tuhin S. ; Verma, Kirti...
Reaction Chemistry & Engineering. 6 (2021) 12 - p. 2270-2279 , 2021

Link: https://doi.org/10.1039/..

3

Studies on the Solid Oxide Cell Perovskite Electrode Materi..:

Shenoy, Chaitra S. ; Patil, Sunaina S. ; Govardhan, P....
Emission Control Science and Technology. 5 (2019) 4 - p. 342-352 , 2019

Link: https://doi.org/10.1007/..

4

Risk Factors for Pre-CAR-T Attrition Among Large B-Cell Lym..:

Wuliji, Natalie ; Banerjee, Rahul ; Liang, Emily C....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S362-S363 , 2024

Link: https://doi.org/10.1016/..

5

Author Correction: Modulating the dynamics of NFκB and PI3K..:

Sherekar, Shubhank ; Todankar, Chaitra S. ; Viswanathan, Ganesh A.
npj Systems Biology and Applications. 10 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

6

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Su..:

Ho, Carrie ; Gopal, Ajay K. ; Till, Brian G....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 2 - p. e33-e39.e1 , 2024

Link: https://doi.org/10.1016/..

7

Acalabrutinib in Combination with Anti-CD19 Chimeric Antige..:

Poh, Christina ; Chow, Victor A ; Lynch, Ryan C...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S33 , 2024

Link: https://doi.org/10.1016/..

8

Post-CAR-T Checkpoint Inhibition Can Result in Durable Resp..:

Banerjee, Rahul ; Lynch, Ryan C ; Wu, Qian Vicky...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S399-S400 , 2024

Link: https://doi.org/10.1016/..

9

POSTER: MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre..:

Wang, Michael L. ; Shah, Nirav N. ; Jurczak, Wojciech...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S213 , 2023

Link: https://doi.org/10.1016/..

10

MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated..:

Wang, Michael L. ; Shah, Nirav N. ; Jurczak, Wojciech...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S459 , 2023

Link: https://doi.org/10.1016/..

11

Efficacy, safety, and molecular response predictors of oral..:

Graf, Solomon A. ; Lynch, Ryan C. ; Ujjani, Chaitra S....
Blood Advances. 7 (2023) 5 - p. 687-696 , 2023

Link: https://doi.org/10.1182/..

12

Polatuzumab vedotin with infusional chemotherapy for untrea..:

Lynch, Ryan C. ; Poh, Christina ; Ujjani, Chaitra S....
Blood Advances. 7 (2023) 11 - p. 2449-2458 , 2023

Link: https://doi.org/10.1182/..

13

Modulating the dynamics of NFκB and PI3K enhances the ensem..:

Sherekar, Shubhank ; Todankar, Chaitra S. ; Viswanathan, Ganesh A.
npj Systems Biology and Applications. 9 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

14

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-C..:

Scarfò, Lydia ; Patel, Manish R. ; Eyre, Toby A....
HemaSphere. 7 (2023) S3 - p. e852670f , 2023

Link: https://doi.org/10.1097/..

15

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED ..:

Jurczak, Wojciech ; Luigi Zinzani, Pier ; Eyre, Toby A....
HemaSphere. 7 (2023) S3 - p. e45636b5 , 2023

Link: https://doi.org/10.1097/..